Dicerna Pharmaceuticals Logo

Email this page: News Release

Dicerna Files Clinical Trial Application for DCR-PHXC, the Company's Most Advanced GalXC™ Product Candidate, for Phase 1 Study in Primary Hyperoxaluria (PH)

For security reasons, registration is required before you can use this feature.
* Indicates required field